Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21841712 | 0.76 | KDM4E (0.48) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL1783862 | 0.74 | ENPP2 (0.42) | ENPP2KDM4EALDH1A1 | |
| SCHEMBL247773 | 0.73 | ENPP2 (0.52) | ENPP2PIK3C3 | |
| SCHEMBL30582972 | 0.72 | ENPP2 (0.55) | ENPP2KDM4EKMT2A | |
| SCHEMBL29952118 | 0.71 | KDM4E (0.37) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL28967087 | 0.70 | ENPP2 (0.36) | ENPP2KDM4EALDH1A1 | |
| SCHEMBL15870163 | 0.69 | PIK3C3 (0.42) | ENPP2MEN1ALDH1A1KMT2APIK3C3 | |
| SCHEMBL29538949 | 0.66 | HCAR2 (0.45) | ENPP2 | |
| SCHEMBL27969 | 0.66 | HCAR2 (0.45) | ENPP2 | |
| SCHEMBL31286902 | 0.66 | LMNA (0.41) | KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133958-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| WO-2023069644-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | MEKANISTIC THERAPEUTICS LLC (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133958-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | EGFR, ERBB2, ERBB3 | ENPP2 588/4885KDM4E 2981/4885MEN1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.